These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Listed as ongoing, but also has a completion date 2004-004957-24 European Cooperative Study of Primary Systemic Therapy 2008-12-18 bad-data
Not reported 2005-005384-28 Randomized study of high-dose chemotherapy plus rituximab (R-HDS) vs conventional chemotherapy with rituximab (R-FC) in chronic lymphocytic leukemia at high risk. 2014-01-27 due-trials
Completed, but no date 2006-002524-42 Use of mieloablative doses of zevalin in aggressive lymphomas of the elderly. Prospective randomized study Z-HDS1,2 vs R-CHOP bad-data
Completed, but no date 2006-004815-24 Bortezomib and dexamethasone treatment before donor lymphocyte infusions for myeloma patients progressing or relapsing after allogeneic transplantation of hematopoietic cells bad-data
Not reported 2007-001416-23 A Multinational Double-Blind, Randomized Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or... 2013-01-16 due-trials
Completed, but no date 2009-009431-30 PHASE III STUDY COMPARING RITUXIMAB-SUPPLEMENTED ABVD (R-ABVD) WITH ABVD FOLLOWED BY INVOLVED-FIELD RADIOTHERAPY (ABVD-RT) IN LIMITED-STAGE (STAGE I-IIA WITH NO AREAS OF BULK) HODGKIN’S LYMPHOMA. bad-data
Not reported 2011-000155-16 Modulation of response to hormonal therapy with lapatinib and/or metformin in patients with HER2-negative, ER and/or PgR positive metastatic breast cancer with progressive disease after first-line hor... 2014-01-31 due-trials
Ongoing 2012-003481-41 Neoadjuvant chemotherapy with nab-paclitaxel in women with HER2-negative high-risk breast cancer ETNA (Evaluating Treatment with Neoadjuvant Abraxane) not-yet-due
Completed, but no date 2012-004508-36 Brentuximab vedotin (SGN-35) as salvage therapy for males with advanced and platinum-resistant germ-cell tumors. An open label, single group, Phase 2 trial bad-data
Ongoing 2014-001984-11 “Neo-Adjuvant Treatment with the CDK4,6 inhibitor Palbociclib in HER2-positive and ER-positive breast cancer: effect on Ki67 and apoptosis before, during and after treatment “ not-yet-due
Ongoing 2014-005017-23 Neo-Adjuvant study with the PDL1-directed antibody in Triple Negative, Early High-Risk and Locally Advanced Breast Cancer undergoing treatment with nab-paclitaxel and carboplatin not-yet-due